$8.7M
The funding round will support the development of hospital-ready diagnostic products and broaden clinical access to glycan testing.
"Together with genetics, the concept of personalised medicine requires a dynamic approach. Genomics provides the blueprint of where we begin, but health is not static—it evolves with time, environment, and lifestyle. To truly transform care, we must complement genomic insights with modifiable biomarkers: biological signals that capture real-time responses to interventions and track improvement longitudinally. This synergy between genomics and adaptive biomarkers is the cornerstone for turning personalised medicine from a descriptive concept into actionable, measurable, and preventative healthcare."
